MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	9/28/2005 10:28:44 AM
	Read Replies (2) of 1826

MGI Pharma "outperform," estimates reduced Wednesday, September 28, 2005 8:18:00 AM ET Robert W. Baird NEW YORK, September 28 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on MGI Pharma Inc (MOGN.NAS), while reducing their estimates for the company. The target price is set to $35. In a research note published this morning, the analysts mention that the company has reduced its FY05 sales guidance for Aloxi from $260 million to $250-$260 million. The lower-end of the new guidance range implies 57% y/y sales growth, the analysts say. The non-GAAP fully taxed EPS estimate for FY05 has been reduced from $0.51 to $0.46.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next